Market Overview

Sucampo Receives $15M Milestone Payment from Abbott for AMITIZA

Related SCMP
Trading Pro Discusses The 'Honey Badger' Stock He Just Bought
Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin
Premarket Biotech Digest: Natural Killer Cells, Lipocine NDA, FDA Calendar (Seeking Alpha)

Sucampo Pharmaceuticals. (NASDAQ: SCMP) today announced that
its subsidiary, Sucampo AG, has received a $15 million milestone payment
from Abbott's (NYSE: ABT) subsidiary, Abbott Japan Co., Ltd. (Abbott),
pursuant to the existing license, commercialization, and supply
agreement between Sucampo Pharma Ltd. (SPL), SPI's subsidiary, and
Abbott. The milestone payment was triggered by the first sale of AMITIZA®
(lubiprostone) capsule 24 μg in Japan. AMITIZA is available through
Abbott in Japan as a prescription medication for chronic constipation
not caused by organic diseases, and was launched to primary care and
specialist physicians on November 21, 2012.

“For years, millions of patients in Japan have been suffering from
chronic constipation,” said Sucampo's Chairman,

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (SCMP + ABT)

Get Benzinga's Newsletters